AGEN — AGENUS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1098972 ·
Last close
$3.32
Market Cap
$138.25M
52W High
$5.08
52W Low
$2.90
ADV30
944,794
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 33,736,000 | 21,914,000 | 15,054,000 | 39,226,000 | 186,456,000 | 34,996,000 | 414,439,000 |
| Dec 2025 | 34,204,000 | 26,693,000 | 14,398,000 | -10,578,000 | 226,798,000 | 2,998,000 | 504,659,000 |
| Sep 2025 | 30,235,000 | 5,997,000 | -4,863,000 | 63,914,000 | 233,891,000 | 3,458,000 | 514,759,000 |
| Jun 2025 | 25,691,000 | -1,262,000 | -16,780,000 | -27,955,000 | 185,221,000 | 9,534,000 | 521,529,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,195,000
Investing CF
$1,194,000
Financing CF
$36,593,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
$-87,000
EPS Diluted TTM
$-3.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,182,765,000
Inventory
—
Receivables
$7,010,000
ST Investments
—
EBIT TTM
$52,190,000
Pretax Income TTM
$-3,083,000
Interest Exp TTM
$55,273,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$123,866,000
EBITDA
$15,188,000
Free Cash Flow
$-50,640,876
Enterprise Value
$128,823,960
Total Cash
$34,996,000
Total Debt
$41,074,000
Shares Out
41,642,431
Trailing EPS
$2.05
Book Value
$-5.74
ROE
—
ROA
2.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 114,196,000 | -20,556,000 | 115,000 | 226,798,000 | 504,659,000 | — | -77,195,000 |
| Dec 2024 | 103,463,000 | -124,429,000 | -227,212,000 | 226,271,000 | 532,695,000 | — | -158,315,000 |
| Dec 2023 | 156,314,000 | -160,105,000 | -245,761,000 | 313,913,000 | 462,295,000 | — | -224,202,000 |
| Dec 2022 | 98,024,000 | -180,242,000 | -220,074,000 | 413,556,000 | 468,458,000 | — | -175,373,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | $133.51M | $2.33 | — |
| CRDF | Cardiff Oncology, Inc. | $132.64M | $1.94 | — |
| ACOG | Alpha Cognition Inc. | $128.03M | $5.88 | — |
| CRDL | Cardiol Therapeutics Inc. | $149.85M | $1.30 | — |
| MOLN | MOLECULAR PARTNERS AG | $151.92M | $4.05 | — |
News headlines (Yahoo Finance, 1h cache)
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
2026-05-26 16:31 · Yahoo
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
2026-05-21 21:00 · Yahoo
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
2026-05-21 21:00 · Yahoo
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
2026-05-15 20:11 · Yahoo
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates
2026-05-12 00:05 · Yahoo
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
2026-05-11 15:50 · Yahoo
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
2026-05-11 12:45 · Yahoo
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
2026-05-08 17:17 · Yahoo
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
2026-05-07 17:37 · Yahoo
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
2026-05-07 17:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.